Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update By Investing.com

0
80
Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update By Investing.com

– Management will hold a conference call on Thursday, May 2 at 4:30  p.m. ET/1:30 p.m. PT  –

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading.

Conference Call and Webcast

Cardiff Oncology will host a conference call and live webcast at  4:30 p.m. ET/1:30 p.m. PT  on  May 2, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of the company’s website at  https://investors.cardiffoncology.com/news-events/events. A replay will be available in the investor relations section on the company’s website following the completion of the call.

About Cardiff Oncology, Inc.Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company’s lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company’s broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.

Cardiff Oncology Contact:James LevineChief Financial Officer858-952-7670jlevine@cardiffoncology.com

Investor Contact:Kiki Patel, PharmDGilmartin Group332-895-3225Kiki@gilmartinir.com

Media Contact:Grace SpencerTaft Communications609-583-1151grace@taftcommunications.com



Source link